Skip to main content
. 2023 Oct 30;11(10):e007047. doi: 10.1136/jitc-2023-007047

Figure 1.

Figure 1

Study design for analysis of patient samples from the IMpower010 trial using the SP263 and 22C3 IHC assays to measure tumor cell PD-L1 levels. a Twenty samples were non-evaluable by both the 22C3 and SP263 assays. BEP, biomarker-evaluable population; IHC, immunohistochemistry; ITT, intention to treat; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1.